98319-24-5

Basic information

• Product Name: Dihydroproscar
• Synonyms: N-TERT-BUTYL-3-OXO-4-AZA-5ALPHA-ANDROSTANE-17BETA-CARBOXAMIDE;N-T-BUTYL-4-AZA-5-ALPHA-ANDROSTA-3-ONE-17BETA-CARBOXAMIDE;N-(1,1-DIMETHYLETHYL)-3-OXO-4-AZA-5A-ANDRO-STANE-17B-CARBOXAMIDE;(4AR,4BS,6AS,7S,9AS,9BS,11AR)-4A,6A-DIMETHYL-2-OXO-HEXADECAHYDRO-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE;4A,6A,11A-TRIMETHYL-2-OXO-HEXADECAHYDRO-INDENO[5,4-F]QUINOLINE-7-CARBOXYLIC ACID TERT-BUTYLAMIDE;3-OXO-4-AZA-5A-ANDROSTANE-17-BETA-(N-TERT-BUTYLCARBOXAMIDE);3-oxo-4-aza-5a-androstane-17b-(n-tert-butylcarboxamide);3-OXO-4-AZA-5-ALPHA-ANDROSTANE-17-BETA-N-T-BUTYLCARBOXAMIDE
• CAS NO: 98319-24-5
• Molecular Formula: C₂₃H₃₈N₂O₂
• Molecular Weight: 374.56
• Product Categories: INTERMEDIATESOFFINASTERIDE;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 98319-24-5.mol
• Article Data: 19

Chemical Properties

• Melting Point: 273-275 °C
• Boiling Point: 569.397 °C at 760 mmHg
• Flash Point: 171.728 °C
• Appearance: yellow/powder
• Density: 1.051 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: −20°C
• Solubility: Chloroform (Slightly), Methanol
• PKA: 15.94±0.70(Predicted)
• CAS DataBase Reference: Dihydroproscar(CAS DataBase Reference)
• NIST Chemistry Reference: Dihydroproscar(98319-24-5)
• EPA Substance Registry System: Dihydroproscar(98319-24-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 98319-24-5(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 98319-24-5 differently. You can refer to the following data:
1. The reduced product of Finasteride (F342000): a mechanism-based inhibitor of human prostate and skin steroid 5α-reductase. It forms an enzyme-bound NADP-dihydrofinasteride adduct during this inhibitor y process.
2. Dihydro Finasteride (Finasteride EP Impurity A) is the reduced product of Finasteride (F342000): a mechanism-based inhibitor of human prostate and skin steroid 5α-reductase. It forms an enzyme-bound NADP-dihydrofinasteride adduct during this inhibitory process.

InChI:InChI=1/C23H38N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h14-18H,6-13H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1

Upstream product

• 830325-86-5 benzothiazolyl 3-oxo-4-aza-5α-androstane-17β-thiocarboxylate 
• 75-64-9 tert-butylamine 
• 103335-55-3 3-oxo-4-aza-5α-androstane-17β-carboxylic acid 
• 73671-92-8 3-oxo-4-aza-5α-androstane-17β-carboxylic acid methyl ester 
• 190006-01-0 17β-(N-tert-butyl)-carbamoyl-5-oxo-A-nor-3,5-secoandrostane-3-oic acid 
• 57072-90-9 3-oxoandrost-4-ene-17β-carboxylic acid chloride 
• 131267-80-6 N-(1,1-dimethylethyl)-3-oxoandrost-4-ene-17β-carboxamide 
• 302-97-6 androst-4-en-3-one-17β-carboxylic acid 
• 51478-09-2 4-aza-5α-androstene-3,17-dione 
• 6857-88-1 3-((3aS,5aS,6R,9aR,9bS)-3a,6-dimethyl-3,7-dioxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid 
• 63-05-8 Androstenedione 
• 877080-58-5 4-aza-5-androstene-17α-hydroxy-17β-cyano-3-one 
• 877080-59-6 4-aza-androst-5,16-diene-17-cyano-3-one 
• 167982-07-2 3-oxo-4-azaandrosta-5,16-diene-17-(N-tert-butylcarboxamide) 

Downstream Products

• 684215-49-4 N-tert-butyl-2-phenylsulfenyl-3-oxo-4-aza-5α-androstane-17β-carboxamide 
• 1329611-51-9 C₂₃H₃₄N₂O₂ 
• 98319-26-7 finasteride 
• 943823-27-6 C₃₁H₄₄N₂O₃ 
• 943823-22-1 C₃₀H₄₁N₃O₅ 
• 943823-23-2 C₃₀H₄₁N₃O₅ 
• 943823-24-3 C₃₀H₄₁N₃O₅ 
• 943823-26-5 C₃₁H₄₄N₂O₄ 
• 123-31-9 hydroquinone 

Relevant articles and documents

Synthesis and comprehensive structural and physicochemical characterization of dutasteride hydrochloride hydrate solvates

Four crystalline dutasteride hydrochloride hydrate solvates containing respectively methanol, ethanol, acetone and acetonitrile molecules were obtained. All samples were characterized by extensive spectroscopic analysis with infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and 1H as well as 13C NMR techniques. For three solvates, i.e. methanol, ethanol and acetone solvates, the single crystal X-ray diffraction (SCXRD) experiments were possible, and their respective crystal and molecular structures were determined. The present study allowed to unambiguously establish the molecular composition of solvates as consisting of a dutasteride: hydrogen chloride: water: solvent in a molar ratio of 1:1:1:1 and confirm that they are isostructural. Beyond providing the full spectroscopic characteristic of the compounds, the results obtained have also allowed clarifying of some appearing inconsistencies in published literature regarding the appropriate attribution of IR absorption bands to the relevant molecular vibrations.

Impurities in finasteride: Identification, synthesis, characterization and control of potential carry-over impurities from reagents used for the process

An assessment of the impurity profile of finasteride and possible carry-over related substances likely to arise during the synthesis of finasteride is described in this article. Impurities in reaction mass were monitored by HPLC, potential impurities isolated with preparative HPLC and structures were substantiated by 1H NMR, MS and MS-MS. Impurities RRT's were established by HPLC co-injection. Based on the spectral data structure of impurity I and impurity II were characterized as cyclohexyl and phenyl analog of finasteride.

PROCESSES TO PREPARE FINASTERIDE POLYMORPHS

Processes for preparing polymorphic crystalline Form I and Form III of finasteride.